| [1] |
Siegel RL, Miller KD, Fuchs HE, et al. Cancer Statistics, 2021 [J]. CA Cancer J Clin, 2021, 71(1): 7-33.
|
| [2] |
李星, 曾晓勇. 中国前列腺癌流行病学研究进展 [J]. 肿瘤防治研究, 2021, 48(1): 98-102.
|
| [3] |
Miki J, Egawa S. The role of lymph node dissection in the management of prostate cancer [J]. Int J Clin Oncol, 2011, 16(3): 195-202.
|
| [4] |
Lestingi JFP, Guglielmetti GB, Trinh QD, et al. Extended versus limited pelvic lymph node dissection during radical prostatectomy for intermediate- and high-risk prostate cancer: early oncological outcomes from a randomized phase 3 trial [J]. Eur Urol, 2021, 79(5): 595-604.
|
| [5] |
Heidenreich A, Ohlmann CH, Polyakov S. Anatomical extent of pelvic lymphadenectomy in patients undergoing radical prostatectomy [J]. Eur Urol, 2007, 52(1): 29-37.
|
| [6] |
Mattei A, Fuechsel FG, Bhatta Dhar N, et al. The template of the primary lymphatic landing sites of the prostate should be revisited: results of a multimodality mapping study [J]. Eur Urol, 2008, 53(1): 118-125.
|
| [7] |
Joniau S, Van den Bergh L, Lerut E, et al. Mapping of pelvic lymph node metastases in prostate cancer [J]. Eur Urol, 2013, 63(3): 450-458.
|
| [8] |
Sanda MG, Cadeddu JA, Kirkby E, et al. Clinically localized prostate cancer: aua/astro/suo guideline. part ii: recommended approaches and details of specific care options[J]. J Urol, 2018, 199(4): 990-997.
|
| [9] |
Mottet N, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer-2020 update. Part 1: screening, diagnosis, and local treatment with curative intent[J]. Eur Urol, 2021, 79(2): 243-262.
|
| [10] |
Gandaglia G, Ploussard G, Valerio M, et al. A novel nomogram to identify candidates for extended pelvic lymph node dissection among patients with clinically localized prostate cancer diagnosed with magnetic resonance imaging-targeted and systematic biopsies [J]. Eur Urol, 2019, 75(3): 506-514.
|
| [11] |
Leyh-Bannurah S R, Budaus L, Pompe R, et al. North american population-based validation of the national comprehensive cancer network practice guideline recommendation of pelvic lymphadenectomy in contemporary prostate cancer [J]. Prostate, 2017, 77(5): 542-548.
|
| [12] |
Fossati N, Willemse PM, Van den Broeck T, et al. The benefits and harms of different extents of lymph node dissection during radical prostatectomy for prostate cancer: a systematic review [J]. Eur Urol, 2017, 72(1): 84-109.
|
| [13] |
Tafuri A, Amigoni N, Rizzetto R, et al. Obesity strongly predicts clinically undetected multiple lymph node metastases in intermediate- and high-risk prostate cancer patients who underwent robot assisted radical prostatectomy and extended lymph node dissection [J]. Int Urol Nephrol, 2020, 52(11): 2097-2105.
|
| [14] |
Arnold M, Leitzmann M, Freisling H, et al. Obesity and cancer: An update of the global impact[J]. Cancer Epidemiol, 2016, 41: 8-15.
|
| [15] |
Porcaro A, Tafuri A, Sebben M, et al. High body mass index predicts multiple prostate cancer lymph node metastases after radical prostatectomy and extended pelvic lymph node dissection[J]. Asian J Androl, 2020, 22(3): 323-329.
|
| [16] |
Arai Y, Yoshiki T, Yamabe H, et al. Value of prostate-specific antigen measurements in predicting lymph node involvement in prostatic cancer [J]. Urol Int, 1990, 45(6): 356-360.
|
| [17] |
Briganti A, Karakiewicz PI, Chun FK, et al. Obesity does not increase the risk of lymph node metastases in patients with clinically localized prostate cancer undergoing radical prostatectomy and extended pelvic lymph node dissection [J]. Int J Urol, 2009, 16(8): 676-681.
|
| [18] |
Yiakoumos T, Kälble T, Rausch S. Prostate-specific antigen density as a parameter for the prediction of positive lymph nodes at radical prostatectomy [J]. Urol Ann, 2015, 7(4): 433-437.
|
| [19] |
Nandakumar V, Bornhorst JA, Algeciras-Schimnich A. Evaluation of clinical performance for the detection of prostate cancer in routine clinical practice[J]. Ann Clin Lab Sci, 2021, 51(1): 3-11.
|
| [20] |
Fossati N, Buffi NM, Haese A, et al. Preoperative prostate-specific antigen isoform p2psa and its derivatives, %p2psa and prostate health index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer: results from a multicentric european prospective study[J]. Eur Urol, 2015, 68(1): 132-138.
|
| [21] |
Schumacher MC, Burkhard FC, Thalmann GN, et al. Is pelvic lymph node dissection necessary in patients with a serum PSA<10 ng/ml undergoing radical prostatectomy for prostate cancer? [J]. Eur Urol, 2006, 50(2): 272-279.
|
| [22] |
Wenger H, Weiner AB, Razmaria A, et al. Risk of lymph node metastases in pathological gleason score≤6 prostate adenocarcinoma: Analysis of institutional and population-based databases [J]. Urol Oncol, 2017, 35(1): 31. e1-31. e6.
|
| [23] |
Daugherty M, Sedaghatpour D, Bratslavsky G, et al. Is pelvic lymph node dissection necessary in patients with biopsy proven Gleason 6 prostate cancer? - analysis of the SEER database[J]. Can J Urol, 2018, 25(4): 9414-9420.
|
| [24] |
Porcaro AB, de Luyk N, Corsi P, et al. Clinical factors predicting and stratifying the risk of lymph node invasion in localized prostate cancer[J]. Urol Int, 2017, 99(2): 207-214.
|
| [25] |
Heidenreich A, Pfister D, Thuer D, et al. Percentage of positive biopsies predicts lymph node involvement in men with low-risk prostate cancer undergoing radical prostatectomy and extended pelvic lymphadenectomy [J]. BJU Int, 2011, 107(2): 220-225.
|
| [26] |
Hövels AM, Heesakkers RAM, Adang EM, et al. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis [J]. Clinical Radiology, 2008, 63(4): 387-395.
|
| [27] |
Peabody H, Lane BR, Qi J, et al. Limitations of abdominopelvic CT and multiparametric MR imaging for detection of lymph node metastases prior to radical prostatectomy [J]. World J Urol, 2021, 39(3): 779-785.
|
| [28] |
Klingenberg S, Jochumsen MR, Ulhoi BP, et al. (68)Ga-PSMA PET/CT for primary lymph node and distant metastasis nm staging of high-risk prostate cancer[J]. J Nucl Med, 2021, 62(2): 214-220.
|
| [29] |
Jansen BHE, Bodar YJL, Zwezerijnen GJC, et al. Pelvic lymph-node staging with (18)F-DCFPyL PET/CT prior to extended pelvic lymph-node dissection in primary prostate cancer - the SALT trial [J]. Eur J Nucl Med Mol Imaging, 2021, 48(2): 509-520.
|
| [30] |
Selnaes KM, Kruger-Stokke B, Elschot M, et al. (18)F-Fluciclovine PET/MRI for preoperative lymph node staging in high-risk prostate cancer patients[J]. Eur Radiol, 2018, 28(8): 3151-3159.
|
| [31] |
Xu N, Ke ZB, Chen YH, et al. Risk factors for pathologically confirmed lymph nodes metastasis in patients with clinical t2n0m0 stage prostate cancer [J]. Front Oncol, 2020, 10: 1547.
|
| [32] |
Huang C, Song G, Wang H, et al. Preoperative PI-RADS Version 2 scores helps improve accuracy of clinical nomograms for predicting pelvic lymph node metastasis at radical prostatectomy [J]. Prostate Cancer Prostatic Dis, 2020, 23(1): 116-126.
|
| [33] |
Cimino S, Reale G, Castelli T, et al. Comparison between Briganti, Partin and MSKCC tools in predicting positive lymph nodes in prostate cancer: a systematic review and meta-analysis [J]. Scand J Urol, 2017, 51(5): 345-350.
|
| [34] |
Oderda M, Diamand R, Albisinni S, et al. Indications for and complications of pelvic lymph node dissection in prostate cancer: accuracy of available nomograms for the prediction of lymph node invasion [J]. BJU Int, 2021, 127(3): 318-325.
|
| [35] |
Gao X, Li LY, Rassler J, et al. Prospective study of crmp4 promoter methylation in prostate biopsies as a predictor for lymph node metastases[J]. J Natl Cancer Inst, 2017, 109(6)：1-9.
|
| [36] |
Tsaur I, Hennenlotter J, Oppermann E, et al. PCA3 and PSA gene activity correlates with the true tumor cell burden in prostate cancer lymph node metastases [J]. Cancer Biomark, 2015, 15(3): 311-316.
|
| [37] |
Heck MM, Retz M, Bandur M, et al. Molecular lymph node status for prognostic stratification of prostate cancer patients undergoing radical prostatectomy with extended pelvic lymph node dissection [J]. Clin Cancer Res, 2018, 24(10): 2342-2349.
|
| [38] |
van der Poel HG, Wit EM, Acar C, et al. Sentinel node biopsy for prostate cancer: report from a consensus panel meeting [J]. BJU Int, 2017, 120(2): 204-211.
|
| [39] |
Mazzone E, Dell'Oglio P, Grivas N, et al. Diagnostic value, oncological outcomes and safety profile of image-guided surgery technologies during robot-assisted lymph node dissection with sentinel node biopsy for prostate cancer [J]. J Nucl Med, 2021, 62(10): 1363-1371.
|
| [40] |
Harke NN, Godes M, Wagner C, et al. Fluorescence-supported lymphography and extended pelvic lymph node dissection in robot-assisted radical prostatectomy: a prospective, randomized trial [J]. World J Urol, 2018, 36(11): 1817-1823.
|
| [41] |
Shimbo M, Endo F, Matsushita K, et al. Impact of indocyanine green-guided extended pelvic lymph node dissection during robot-assisted radical prostatectomy [J]. Int J Urol, 2020, 27(10): 845-850.
|
| [42] |
Claps F, Ramirez-Backhaus M, Mir Maresma MC, et al. Indocyanine green guidance improves the efficiency of extended pelvic lymph node dissection during laparoscopic radical prostatectomy [J]. Int J Urol, 2021, 28(5): 566-572.
|
| [43] |
Grivas N, Wit E, Tillier C, et al. Validation and head-to-head comparison of three nomograms predicting probability of lymph node invasion of prostate cancer in patients undergoing extended and/or sentinel lymph node dissection [J]. Eur J Nucl Med Mol Imaging, 2017, 44(13): 2213-2226.
|
| [44] |
Winter A, Engels S, Goos P, et al. Accuracy of magnetometer-guided sentinel lymphadenectomy after intraprostatic injection of superparamagnetic iron oxide nanoparticles in prostate cancer: the sentimag pro Ii study [J]. Cancers (Basel), 2019, 12(1): 32.
|
| [45] |
Hinsenveld FJ, Wit EMK, van Leeuwen PJ, et al. Prostate-specific membrane antigen pet/ct combined with sentinel node biopsy for primary lymph node staging in prostate cancer [J]. J Nucl Med, 2020, 61(4): 540-545.
|
| [46] |
Van Den Eeden SK, Lu R, Zhang N, et al. A Biopsy-based 17-gene genomic prostate score as a predictor of metastases and prostate cancer death in surgically treated men with clinically localized disease [J]. Eur Urol, 2018, 73(1): 129-138.
|
| [47] |
Eggener S, Karsh LI, Richardson T, et al. A 17-gene panel for prediction of adverse prostate cancer pathologic features: prospective clinical validation and utility[J]. Urology, 2019, 126: 76-82.
|
| [48] |
Covas Moschovas M, Chew C, Bhat S, et al. Association Between Oncotype DX Genomic Prostate Score and Adverse Tumor Pathology After Radical Prostatectomy [J]. Eur Urol Focus, 2022, 8(2): 418-424.
|
| [49] |
Zhu LF, Song LD, Xu Q, et al. Highly expressed long non-coding rna fezf1-as1 promotes cells proliferation and metastasis through notch signaling in prostate cancer[J]. Eur Rev Med Pharmacol Sci, 2019, 23(12): 5122-5132.
|
| [50] |
Xia Q, Li J, Yang Z, et al. Long non-coding RNA small nucleolar RNA host gene 7 expression level in prostate cancer tissues predicts the prognosis of patients with prostate cancer[J]. Medicine (Baltimore), 2020, 99(7): e18993.
|